{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"800"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Recommended Phase 2 dose (RP2D) of tazemetostat as administered orally twice daily (BID), continuously in 28-day cycles in subjects with advanced solid tumors or with relapsed and/or refractory B cell lymphomas as determined by incidence, seriousness, toxicity grade, and relatedness of treatment emergent dose limiting toxicities","groups":[{"description":"Patients in the Phase 1 portion of the study. Tazemetostat: Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.","id":"OG000","title":"Phase 1"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The first 28-day cycle of therapy","title":"Recommended Phase 2 Dose (RP2D) of Tazemetostat as a Single-Agent and in Combination With Prednisolone (Phase 1 Only)","type":"PRIMARY","unitOfMeasure":"mg BID"}